The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th Edition

This edition features a demonstrative increase of hundreds of pages from the 2010 edition as new companies have entered the diagnostic market and IT companies make their mark on diagnostics.  

In eight best-selling editions, Shara Rosen has detailed the market for in vitro diagnostic (IVD) testing, throughout the world,  in one complete volume. The report, The Worldwide Market for In Vitro Diagnostic Tests, is a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry.

Comprehensive Coverage of a High Interest Industry

This year, Kalorama has published its eighth edition of this informative volume based on the market events of 2011. The report is over 1400 pages, reflecting the dramatic change in IVD.  New entrants, net technologies have entered the stage and all important events are cataloged in this report.  The idea behind Kalorama's unique report is that the entire market can be captured in one volume and business planners avoid multiple purchases. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:

• Point of Care (POC), (Professional and Self-Testing)
• Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)
• Core Lab (General Chemistries, Workstations, Analyzers)
• Immunoassays (Blood Gases, Urinalysis, Critical Care)
• Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
• Hematology
• Coagulation (Lab-Based, POC, Genetic Markers)
• Microbiology and Virology
• Blood Banking (Grouping, Immunoassay Screens, NAT Screens)

Market sizes, forecasts and shares are provided, as well as a geographic breakdown of the segments, where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market numbers are presented for 2011, with projections given through 2016.

The "Bible of the IVD Industry"

Now in 8 editions, this report has become the go-to market research reference for the industry.  Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments.  See aspects of the industry that might not be available in your company's internal resources.  View the market from an independent point of view.  Learn about competitors in away that may be invisible to internal personnel.  Know the market players - your competitors and potential partners, in proper context and classification.  Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.

A Global Report

From the first edition, this report was designed as a global resource in order to give market-watchers a true picture of the industry.  IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism, the growth, and also competition is occurring in other areas. Many of the most interesting opportunities for companies are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions.

• North America
• Europe (EU countries, incl. IVD market sizes by country)
• Eastern Europe
• South America
• Asia (Japan, China and India)
• Rest of World

A Report Designed for a Changing Industry

A number of totally disparate phenomena have come together to change the IVD industry. Human genome research is finding links between a person’s genome and several lifestyle situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions. This has attracted consumer product companies such as Proctor & Gamble and Nestlé to develop products and services based on IVD technologies. Decreases in life science grants has encouraged companies active in this space to migrate their technologies for clinical applications.